TGFB1 and coronary artery disorder: The reduced transcriptional activity of TGF‐β1 and its type III receptor demonstrated in patients with heart failure may be a useful marker in clinical practice for assessing the progression of coronary artery disease towards the development of heart failure, as well as its decompensation and compensation.